Moneycontrol
HomeNewsTrendsCurrent AffairsITC ties up with Linde India to supply 24 cryogenic ISO containers to Centre amid oxygen crisis

ITC ties up with Linde India to supply 24 cryogenic ISO containers to Centre amid oxygen crisis

ITC is already airlifting oxygen containers and its paper unit in Bhadrachalam has begun supplying oxygen to neighbouring areas.

April 24, 2021 / 15:59 IST
Story continues below Advertisement
(Image: Reuters)

At a time when several hospitals across the country are struggling to procure medical oxygen for COVID-19 patients, diversified conglomerate ITC Limited has said it will airlift 24 cryogenic ISO containers from Asian countries in collaboration with Linde India Ltd to help ease the shortage.

The multinational company said: “To serve the national priority and Government’s effort in easing bottleneck of medical oxygen supply to hospitals, ITC is air freighting 24 cryogenic ISO containers from Asian countries in collaboration with Linde India Ltd.” ITC is already airlifting oxygen containers and its paper unit in Bhadrachalam has begun supplying oxygen to neighbouring areas. COVID-19 second wave | India’s oxygen crisis threatens to collapse healthcare system

The company added: “ITC is committed to supporting the Government and it will continue to explore other avenues to help address the emerging challenges.”

Story continues below Advertisement

The Centre has already banned the supply of oxygen for industrial purposes, except in some specified industries, and termed it “essential public health commodity”, in view of the severe oxygen shortage that hospitals are reeling under.

The demand for medical oxygen from states such as Delhi, Gujarat, Maharashtra, Madhya Pradesh, and Uttar Pradesh has increased manifold over the past weeks as India saw a sharp rise in COVID-19 cases in the wake of the second wave of the pandemic.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show